Skip to main content
OpenTrials
Completed

NCT Number: NCT04420273

Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access

The purpose of this study is to reduce melanoma mortality by improving early detection of melanoma with skin self-examination (SSE) among people who self-identify as being at risk and seek care for a concerning mole. Because women are more likely than men to perform SSE, women who are engaged in health promotion by having a recent screening mammogram are the focus of this research. Self-management of melanoma detection with SSE depends on ready access to dermatologists when a concerning mole is detected. In March 2020, the Illinois stay at home order (COVID-19) prohibited non-essential health care, including screening mammography and dermatology office-based care, and both are expected to remain limited until fall 2020. This submission explores a) the effectiveness of targeted melanoma detection (TMD) among women, who identify their risk of having a melanoma, learn to perform SSE, and perform SSE, and b) the effectiveness of adhesive patch-based home sample collection for genomic analysis to rule out melanoma in moles identified by women (who received the intervention) as concerning will be explored.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

Northwestern University Feinberg School of Medicine Department of Dermatology

Chicago, Illinois, 60611, United States

About this study

The proposed work will assess the effectiveness of targeted melanoma detection (TMD) with SSE education delivered remotely to women who had a screening mammogram. The effect of TMD with SSE education will be assessed with a randomized control trial among women served by Northwestern Medicine in rural, suburban and metropolitan communities. Women who identify concerning moles will choose among three options: a) watch the mole to see if the border, color or diameter of the mole changes b) send a picture of the mole to the PI for consideration of mole self-sampling, or c) make an appointment with my healthcare provider to check the mole. As required a physician will supervise women, who will perform non-invasive mole self-sampling with non-invasive adhesive patches for genomic analysis of the concerning pigmented lesion (mole). If the genomic analysis suggests that the concerning mole may be a melanoma, then the recommendation will be to have the mole biopsied.The effectiveness of acquired samples suggestive of melanoma will be examined by the obtaining the pathology reports of biopsied moles. Health care providers' (HCPs) clinical/pathologic assessment of concerning moles will be identified in the Northwestern Medicine electronic health record (EHR) system.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult women (aged 18 and older) with no upper age limit, who had a screening mammogram from January 1, 2019 to February 28, 2020.
  • Able to read English
  • Vision enough to read a newspaper
  • Self-perception of their potential melanoma risk
  • Willing to perform SSE either alone or with a skin check partner
  • Willing to complete monthly surveys for 3 months and receive monthly text messages to personal mobile phone
  • Have home Internet access and phone with ability to take a picture of a mole
  • Have access to Federal Express or US Postal Service Express Mail to send mole self-sampling kits
  • Willing to allow the research team access to their electronic health record to abstract physician assessment of concerning moles, biopsy results and treatment
  • Willing to provide up-to-date email address, mailing address and telephone number

Inclusion criteria

of skin check partner, who may be a man or a woman, to have mole self-sampled

  • Male or female over the age of 18 years
  • Able to read English
  • Vision enough to read a newspaper

Exclusion criteria

  • Male
  • Female under the age of 18
  • Unable to read English

Treatment and study plan

SSE educational intervention

Behavioral

Women participants receive a SSE brochure and three monthly reminders to perform SSE. In the second month, women select goals for SSE.

Active control:Healthy Living

Behavioral

Women participants receive a Healthy Living brochure and three monthly reminders to perform the following activities of healthy living: get quality sleep, walk briskly for 30 min, eat 5 servings of fruits and vegetables a day. In the second month, women select goals for healthy living.

Primary outcomes

  1. Number of Participants Who Completed SSE at Specified Time Points

    Time frame: 90 days

    Self-reported performance of SSE, a custom scale with the frequency and extent of SSE is completed in an online monthly survey

  2. Number of Participants Who Identified Concerning Moles at Specified Time Points

    Time frame: 90 days

    Self-reported identification of concerning mole identified by user assigning scores to the border,color and diameter of the mole. A validated scoring system is used to categorize the border, color and diameter as 1 if normal, 2 if not sure, and 3 if abnormal.The sum of the scores indicates if the mole is concerning (sum of 3= benign, stop checking the mole; sum of 4- 7 monitor the mole for change in the next month; sum of 8-9 = concerning mole make an appointment to see a physician.

Secondary outcomes

  1. Participants' Reported Skin Self-examination Anxiety

    Time frame: 90 days

    Self-reported responses to 6 items, each with a 5-point Likert scale (range 6-30) higher score= more anxiety, a worse outcome

  2. Participants' Confidence Performing Mole Checks

    Time frame: 90 days

    Self-reported responses to 7 items, each with a 5-point Likert scale (range 7-35) higher score = greater confidence (better outcome).

  3. Clinical Diagnosis of Participants Having Any Physician Visits for Concerning Moles

    Time frame: 5 months

    Electronic medical record review of physician's clinical diagnosis of concerning mole during the 3 months of the study and for 2 subsequent months

  4. Pathologic Diagnosis of Concerning Moles

    Time frame: 5 months

    Electronic medical record review of pathologic diagnosis of biopsied moles that participants identified as concerning

  5. Biopsy Performed

    Time frame: 5 months

    EMR review of physician performing a biopsy on a concerning mole identified by the participant, percentage of biopsies performed

Sponsors and collaborators

Lead sponsor

Northwestern University

Other

Registry information

Official study title

Targeted Melanoma Detection With Skin Self-examination: Leveraging the Mammogram Encounter

Acronym: TMD

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Jun 9, 2020
Registry last updated
Nov 23, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.